Noninvasive testing in the diagnosis of metabolic dysfunction-associated steatohepatitis
Authors:
Open Access
- 22 August 2024
- journal article
- review article
- Published by OAE Publishing Inc. in Metabolism and Target Organ Damage
- Vol. 4 (3)
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) [previously termed nonalcoholic fatty liver disease (NAFLD)] is estimated to be the most common chronic liver disease worldwide, affecting 25% of the world’s population and becoming the leading cause of liver transplant in the US. The progression of MASLD from simple hepatic steatosis to the more severe metabolic dysfunction-associated steatohepatitis (MASH) [previously nonalcoholic steatohepatitis (NASH)] has critically important impacts on clinical outcomes. Early detection and staging of disease severity, along with lifestyle modifications and treatment of comorbid conditions, is the best way to prevent the progression or reverse the course of the disease. Although noninvasive imaging and predictive indices are available for the evaluation of hepatic fibrosis, the only way to diagnose MASH remains liver biopsy despite the risk for complications and being less desired by patients. Hence, there is a need to develop noninvasive tests to aid in both the diagnosis and monitoring of MASH, especially with the recent emergence of liver-directed therapy for “at risk” MASH (MASH with NAS ≥ 4 and Stage ≥ F2 Fibrosis). The goal of the current review is to cover the most recent pathophysiology, current diagnostic methods, and recent advances to aid in the diagnosis of MASH.Keywords
This publication has 84 references indexed in Scilit:
- Multiparametric Magnetic Resonance Elastography Improves the Detection of NASH Regression Following Bariatric SurgeryHepatology Communications, 2019
- Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver diseaseCellular and Molecular Life Sciences, 2018
- Metabolomic‐based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohortsHepatology Communications, 2018
- Current and future pharmacological therapies for NAFLD/NASHJournal of Gastroenterology, 2017
- Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐upHepatology, 2014
- Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver diseaseHepatology, 2012
- Performance of the Aspartate Aminotransferase-to-Platelet Ratio Index for the Staging of Hepatitis C-Related Fibrosis: An Updated Meta-Analysis §ΔHepatology, 2010
- Cytokeratin-18 Fragment Levels as Noninvasive Biomarkers for Nonalcoholic SteatohepatitisHepatology, 2009
- Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetesHepatology, 2008
- Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†‡Hepatology, 2006